This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 1997 Nov;154(11):1626.

doi: 10.1176/ajp.154.11.1626.

High-dose olanzapine for treatment-refractory schizophrenia

B B Sheitman, J C Lindgren, J Early, M Sved

PMID: 9356581
DOI: 10.1176/ajp.154.11.1626

High-dose olanzapine for treatment-refractory schizophrenia

B B Sheitman et al. Am J Psychiatry. 1997 Nov.

. 1997 Nov;154(11):1626.

doi: 10.1176/ajp.154.11.1626.

Authors

B B Sheitman, J C Lindgren, J Early, M Sved

PMID: 9356581
DOI: 10.1176/ajp.154.11.1626

No abstract available

PubMed Disclaimer

Comment in

British experience with high-dose olanzapine for treatment-refractory schizophrenia.
Mountjoy CQ, Baldacchino AM, Stubbs JH. Mountjoy CQ, et al. Am J Psychiatry. 1999 Jan;156(1):158-9. doi: 10.1176/ajp.156.1.158a. Am J Psychiatry. 1999. PMID: 9892320 No abstract available.

Similar articles

Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
Martín J, Gómez JC, García-Bernardo E, Cuesta M, Alvarez E, Gurpegui M. Martín J, et al. J Clin Psychiatry. 1997 Nov;58(11):479-83. J Clin Psychiatry. 1997. PMID: 9413413 Clinical Trial.
Adverse effects of high-dose olanzapine in treatment-refractory schizophrenia.
Bronson BD, Lindenmayer JP. Bronson BD, et al. J Clin Psychopharmacol. 2000 Jun;20(3):382-4. doi: 10.1097/00004714-200006000-00017. J Clin Psychopharmacol. 2000. PMID: 10831029 Clinical Trial. No abstract available.
Comparative effectiveness of antipsychotic drugs.
Meibach RC. Meibach RC. Am J Psychiatry. 2003 Mar;160(3):589-90; author reply 592-3. doi: 10.1176/appi.ajp.160.3.589-a. Am J Psychiatry. 2003. PMID: 12611851 No abstract available.
Olanzapine: a new atypical antipsychotic.
Littrell K, Peabody CD, Littrell SH. Littrell K, et al. J Psychosoc Nurs Ment Health Serv. 1996 Aug;34(8):41-6. doi: 10.3928/0279-3695-19960801-18. J Psychosoc Nurs Ment Health Serv. 1996. PMID: 8856604 Review. No abstract available.
[Use of novel agents in the treatment of schizophrenia and a look to the future].
Keks NA. Keks NA. Nihon Shinkei Seishin Yakurigaku Zasshi. 1998 Jun;18(3):97-101. Nihon Shinkei Seishin Yakurigaku Zasshi. 1998. PMID: 9800201 Review. Japanese. No abstract available.

See all similar articles

Cited by

Olanzapine: an updated review of its use in the management of schizophrenia.
Bhana N, Foster RH, Olney R, Plosker GL. Bhana N, et al. Drugs. 2001;61(1):111-61. doi: 10.2165/00003495-200161010-00011. Drugs. 2001. PMID: 11217867 Review.
Treatment-refractory schizophrenia.
Buckley PF, Wiggins LD, Sebastian S, Singer B. Buckley PF, et al. Curr Psychiatry Rep. 2001 Oct;3(5):393-400. doi: 10.1007/s11920-996-0033-z. Curr Psychiatry Rep. 2001. PMID: 11559476 Review.
Haloperidol (oral) versus olanzapine (oral) for people with schizophrenia and schizophrenia-spectrum disorders.
Ibragimov K, Keane GP, Carreño Glaría C, Cheng J, Llosa AE. Ibragimov K, et al. Cochrane Database Syst Rev. 2024 Jul 3;7(7):CD013425. doi: 10.1002/14651858.CD013425.pub2. Cochrane Database Syst Rev. 2024. PMID: 38958149 Free PMC article.
Olanzapine for schizophrenia.
Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S. Duggan L, et al. Cochrane Database Syst Rev. 2005 Apr 18;2005(2):CD001359. doi: 10.1002/14651858.CD001359.pub2. Cochrane Database Syst Rev. 2005. PMID: 15846619 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information